Novavax Inc (NVAX) Quote

As more people listen to the Novavax presentation at the Bank of America 2024 Healthcare Conference, there will be more new investors buying in for the first time, and current investors adding to their existing positions. I expect to see NVAX share price climb higher. We'll get news updates in between earnings that will add fuel to the fire. I don't believe Sanofi is going to be the only partner we sign this year. Another partner with a similar up-front cash and royalty deal will light the fuse on the second rocket engine, with the first rocket engine ignited by the Sanofi deal. Great time to be a NVAX shareholder.

Total Calls i meant

total call 150, will add some tomorrow, if stocks break day high of today

I have $19 Calls also this can run ugly upside since highest short interest and borrowing fee

The BoA conference presentation yesterday is really worth a listen. The BoA analyst did a great job with the questions and investors learned more about the incredible benefits of the Sanofi partnership. I feel fortunate to be an investor here.

Webcast link

May 2024 Investor Presentation - Not part of BoA presentation but recommended

Let’s see here. May base and then rip to +19. Calls are going to pay

That volume…pay day

NVAX new 52 week high
Technicians will say the gap must fill
I say bull shit

+70k. Out till pull back. Daily over parabolic

Bird flu 😷

? why doesn't NVAX show on the Breakout board?

I would love for that to happen...

Wish I had bought more

Today's Sanofi partnership news and subsequent rise in share price likely generated a significant number of margin calls for shorts. Demand for shares should be pretty high next week to cover today's margin calls. Any movement higher will generate even more margin calls. Great time for a big short squeeze. Thanks shorties for the cheap shares I was able to pick up over the last few months.

NVAX
Novavax Inc
8.93
4.45 (99.33%)
Volume: 170,708,691
Day Range: 8.61 - 11.00
Bid: 8.93
Ask: 8.95
Last Trade Time: 7:11:59 PM EDT
Total Trades: 892,437

THANK YOU

Added another 550 shares, now at 17,700 @ $5.32 average cost.

Exciting times ahead for Novavax. Looking forward to seeing what this Sanofi partnership brings to shareholders.

Nice. 10 large her at $7. Follow VWAP

NVAX: Even Global REUTERS can barely handle the EXPANSIVE news still coming-out!! (More just out, below!!)

"BRIEF-Novavax Exec Says Now Anticipate Data Readouts For Both Novavax's Combination Covid-Flu Shot And Standalone Flu Vaccine In Mid 2025"

Same here. 17,150 shares at average cost of $5.17. The partnership announced today negates all of Shah's concerns. I'm revising my votes.

NVAX: This news was SPLATTERED across the entire Planet today, by every conceivable Global News Service. A FRENCH Firm partnership, bringing-in the entire European Union interest here. Then toss-in the USA, Canada, & Western Hemisphere, to boot. Not even to mention monster ASIA & the British Commonwealth. Talk about a potential, a REAL, a COLLOSAL health care MARKET PLACE!!! (And a stock PRICE this incredibly CHEAP???!!! Are you frickin' kidding me???)

thanks for the news.... good news at last... I'm in profit here... love the colour green....

NVAX: This news today goes far, far, BEYOND a simple Covid vaccine deal, Folks!!! Call me straight-up BONKERS, if you like, but this could very well become the Wall Street EXPLOSION of this frickin' YEAR 2024!!!


"Oh, Harry, what in God's name was THAT???!!! --- Fret not, Honey, it was just our NVAX stock investment taking-off on Wall Street today."
//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

Pick me up 14

NVAX: Notwithstanding shares count, shorting, float, inter alia, this puppy could nonetheless be a 10-bagger today, from yesterday's Close. (If I prove to be pathetically STUPID in my prognostication here, well, you can see ME, below, fully admitting just 15-minutes ago my overall Wall Street 'acumen', generally.)

CONGRAT$ ON THAT CALL

AMA

Monday, May 06, 2024 11:18:18 AM👈️

NVAX in Play. Big move coming...

Major Developments
5/10/2024, 6:06:45 AMLicensing deal with Sanofi, $500m upfront and $700m for development.
https://dilutiontracker.com/app/search/NVAX


Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal

https://finance.yahoo.com/news/sanofi-inks-1-2-billion-082615895.html

JUST IN: Huge news from #Novavax ( $NVAX) as they announce a game-changing $1.4 billion deal with Sanofi ( $SNY) 🚀🔬

💸 Partnership Perks:
Sanofi to invest $500M upfront, promising another $700M for hitting key milestones. Plus, an additional $200M to adopt Novavax’s Matrix-M… pic.twitter.com/MpqMqePkcd— Antonio Santiago (@awsan) May 10, 2024

Doesn’t look like at 7:45
Went up too high too fast

Will it grow legs after 9:30

33% short in Finviz on 130m float. That’s a lot shares

Holy margin call

LOL

Damn

Wake up

NVAX in Play. Big move coming...

NVAX under $5

imo...have you guys tried the new hand sanitizer...? .....talk about delicious~ NVAX


NVAX


IHuser

NVAX
Novavax Inc
5.1192
-0.0108 (-0.21%)
Volume: 4,050,875
Day Range: 4.98 - 5.2187
Last Trade Time: 6:11:12 PM EDT
Delayed by 15 minutes

yes, sold a few for a good little profit thank goodness then the sell off today. Grabbed a few during the melee. Looking good for this year IMO.

paying off well so far

ascending pennant,cup and handle forming,this could be the make or break moment here,stop loss set 5.18(my in),its been steady distribution since hod,not looking good with vol fading also,no vol surges either,beating shorts is 1 in a million

$77m traded,wow!!

weekly,monthly charts bullish,currently higher lows and highs,52M shares have to be covered in 8.7 days(they have to cover some time,but will they,dang mm/bank criminals)

Nice jump today.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024

https://ir.novavax.com/press-releases/2024-02-20-Novavax-to-Host-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Operational-Highlights-on-February-28,-2024

Schedule 13G issued for Morgan Stanley 6.2% ownership (7.3M) shares of NVAX.

SEC Filing

NVAX new 52 week low

NVAX new 52 week low

New Phase 3 Trial Data Confirm the Uniquely High Efficacy and Good Safety Profile of the R21/Matrix-M™ Malaria Vaccine in African Children

SERUM INSTITUTE OF INDIA PVT. LTD. — February 1, 2024
https://www.seruminstitute.com/press_release_sii_010224.php

• Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% efficacy in the 5–17-month age group over the first year

• To date 25 million doses manufactured and ready for roll-out by The Serum Institute of India (SII) in the next three to four months

Phase 3 Trial data results of The R21/Matrix-M™ vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax’s Matrix-M™ adjuvant has confirmed high efficacy and supported regulatory approvals and licensure in several African countries. The R21/Matrix-M™ vaccine was designed in 2011 as a potential improvement on the RTS, S/AS01 malaria vaccine designed in the 1980s. A phase II trial in Burkina Faso, reporting in 2021, was the first to show that R21/Matrix-M™ could reach the WHO-specified target of 75% efficacy in African children. Recent WHO endorsement will lead to the initial rollout of R21/Matrix-M™ in the coming months. The new results are published in The Lancet today.

The trial investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% vaccine efficacy over the first year of follow-up across all sites in the 5-17-month-old age group, the age range group which is studied for most malaria vaccines. Efficacy over this period was broadly similar across sites and in different transmission settings. Safety data from the trial have been reassuring with no serious adverse events linked to immunisation. No other vaccine has reported over 55% efficacy in the same age group. A booster dose at a year maintained good efficacy over the following 6-12 months. The vaccine also reduced infection rates in children measured at 12 and 18 months after vaccination suggesting a potentially beneficial effect in reducing malaria transmission.

R21/Matrix-M™ vaccine was well tolerated, with injection site pain and fever as the most frequent adverse events. Number of adverse events of special interest and serious adverse events did not significantly differ between the vaccine groups. There were no treatment-related deaths.

Malaria is the largest cause of death in young African children with over 600,000 deaths globally each year. Two vaccines have recently achieved and completed World Health Organization (WHO) prequalification and initial deployments are starting early this year.

Professor Adrian Hill, chief investigator of the R21/Matrix-M™ phase 3 trial said "The continued high efficacy of this new vaccine in field trials is very encouraging, and consistent with the high efficacy and excellent durability observed in a smaller four-year phase IIb trial. These data support an important role for the unique high-density nanoparticle display, of the conserved repeat region of the malaria parasite circumsporozoite protein, a feature in the design of the R21 vaccine, in providing such high vaccine efficacy and, thereby, an important new tool for malaria control".

Significantly increased immune responses to the R21/Matrix-M™ vaccine and slightly higher vaccine efficacy were observed in 5-17-month-olds compared to 18-36-month-olds malaria vaccines, supporting planned vaccine deployment initially from 5 months of age in young African children.

The vaccine is licensed to the Serum Institute of India (SII), the world’s largest vaccine manufacturer and a long-term partner of the University of Oxford. This is critical because vaccinating those at high risk of malaria will be important in stemming the spread of the disease, as well as protecting the vaccinated. Matrix-M™ adjuvant is manufactured by Novavax AB and provided to Serum Institute of India for formulation into the final vaccine drug product.

Adar Poonawalla, CEO, Serum Institute of India, said: "The Lancet study on R21/Matrix-M™ Phase 3 trials mark a significant advancement in our battle against this global threat. Our collaboration with the University of Oxford has been instrumental in developing the R21/Matrix-M™ malaria vaccine. We are dedicated to making this vaccine available, especially in Africa, where malaria poses a substantial threat to millions of lives, bringing us closer to a malaria-free world".

Professor Alassane Dicko, Principal Investigator in Mali of the R21/Matrix-M™ vaccine, said: "It has been very exciting to generate high efficacy data with the new R21/Matrix-M™ vaccine so quickly. I predict that this vaccine should be very impactful in preventing malaria deaths in African children".

John C Jacobs, CEO of Novavax commented "Approximately 1,300 children die from malaria every day, a staggering statistic for a preventable disease. The R21/Matrix-M™ Phase 3 efficacy data published in The Lancet reinforce the potential of R21/Matrix-M™ vaccine to protect children against this disease. We are proud of the role of Novavax's patented saponin-based Matrix-M™ adjuvant, which has been demonstrated to enhance the immune response, in the outcome of this clinical trial and are eager to see the realized impact of the vaccine when it is rolled out globally".

NVAX
Novavax Inc
4.03
0.00 (0.00%)
Volume: 7,622,424
Day Range: 3.95 - 4.24
Last Trade Time: 4:05:04 PM EST
Delayed by 15 minutes

NVAX new 52=week low